ArticleCancer discovery2021
Genetic Determinants of EGFR-Driven Lung Cancer Growth and Therapeutic Response
Open access · bronzeAbstract read
In one paragraph
Article in Cancer discovery, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
0numbers the graph read from it
0cells of the map it votes in
66citing papers in PubMed
12.9field-weighted citation impact, top 1% of its field
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed, 119 citations in OpenAlex.
- Neoadjuvant sintilimab plus chemotherapy in EGFR-mutant NSCLC: Phase 2 trial interim results (NEOTIDE/CTONG2104).Cell reports. Medicine · 2024Trial
- Polycomb scaffolding subunit EED supports the SCLC neuroendocrine identity and EGFR-mutant LUAD-to-SCLC transformation.The Journal of clinical investigation · 2026Article
- Recent advances in engineered nanozymes for precision lung cancer therapy.Materials today. Bio · 2026Review
- Tumor suppressor genotype influences the extent and mode of immunosurveillance in lung cancer.Nature communications · 2026Article
- Targeting ubiquitin signaling vulnerabilities in KEAP1-inactivated lung cancer.The EMBO journal · 2026Article
- EML4-ALK Variant-Specific Genetic Interactions Shape Lung Tumorigenesis.Cancer discovery · 2026Article
- Fatal Disease Progression Driven by Acquired MET Amplification After EGFR-TKI Therapy in EGFR- and RBM10-Mutant Lung Adenocarcinoma.Cancer management and research · 2026Article
- Clinicopathological and Genomic Analysis ofCancer management and research · 2026Article
- The methylation pattern of osimertinib resistance: prospects for diagnosis and treatment of NSCLC.Frontiers in oncology · 2026Review
- Experimental evolution in an era of molecular manipulation.Nature reviews. Genetics · 2026Review
- Concurrent PIK3CA mutant promotes cachexia through inflammatory signaling in EGFR mutant lung cancer.Nature communications · 2025Article
- SETD2 suppresses tumorigenesis in a KRASeLife · 2025Article
- Splicing Shift of RAC1 Accelerates Tumorigenesis and Defines a Potent Therapeutic Target in Lung Cancer.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Article
- Exosomal FGD5-AS1 promotes proliferation of lung cancer cells under hypoxia by inhibiting miR-1179 and activating P-cadherin.Human cell · 2025Article
- Persistent lineage plasticity driving lung cancer development and progression.Clinical and translational medicine · 2025Review
- Distinct roles for the thioredoxin and glutathione antioxidant systems in Nrf2-Mediated lung tumor initiation and progression.Redox biology · 2025Article
- RBM10 deficiency promotes brain metastasis by modulating sphingolipid metabolism in a BBB model of EGFR mutant lung adenocarcinoma.Journal of experimental & clinical cancer research : CR · 2025Article
- EGFR status assessment using reflex testing targeted next-generation sequencing for resected non-squamous non-small cell lung cancer.Virchows Archiv : an international journal of pathology · 2025Article
- Combinatorial In Vivo Genome Editing Identifies Widespread Epistasis and an Accessible Fitness Landscape During Lung Tumorigenesis.Molecular biology and evolution · 2025Article
- Efficacy of ramucirumab combined with erlotinib or osimertinib in untreated EGFR-mutated NSCLC patients with asymptomatic brain metastases: insights from molecular biomarkers in the RELAY-brain trial.Investigational new drugs · 2025Observational
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
20 authors at 5 institutions in 3 countries.
Giorgia Foggetti *Yale Cancer Center, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0003-1844-1413
Chuan Li *Department of Biology, Stanford University, Stanford, California.ORCID 0000-0002-4381-3891
Hongchen Cai *Department of Genetics, Stanford University School of Medicine, Stanford, California.
Jessica A HellyerDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California.
Wen-Yang LinDepartment of Genetics, Stanford University School of Medicine, Stanford, California.
Deborah AyeniDepartment of Pathology, Yale School of Medicine, New Haven, Connecticut.
Katherine HastingsYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Jungmin ChoiDepartment of Genetics, Yale School of Medicine, New Haven, Connecticut.
Anna WurtzYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Laura AndrejkaDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0002-2202-5626
Dylan G MaghiniDepartment of Genetics, Stanford University School of Medicine, Stanford, California.ORCID 0000-0001-9542-492X
Nicholas RashleighYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Stellar LevyYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Robert HomerYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.ORCID 0000-0002-2055-5885
Scott N GettingerYale Cancer Center, Yale School of Medicine, New Haven, Connecticut.
Maximilian DiehnInstitute for Stem Cell Biology and Regenerative Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-2032-0581
Heather A WakeleeDivision of Oncology, Department of Medicine, Stanford University School of Medicine, Stanford, California.ORCID 0000-0003-1136-980X
Dmitri A PetrovDepartment of Biology, Stanford University, Stanford, California.ORCID 0000-0002-3664-9130
Monte M WinslowDepartment of Genetics, Stanford University School of Medicine, Stanford, California. katerina.politi@yale.edu mwinslow@stanford.edu.
Katerina PolitiYale Cancer Center, Yale School of Medicine, New Haven, Connecticut. katerina.politi@yale.edu mwinslow@stanford.edu.
Yale Cancer Center · USStanford University · USStanford Medicine · USYale University · USCalifornia Institute for Regenerative Medicine · US
Funding
Yale Clinical and Translational Science Award (U Component)UL1TR001863 · NCATS · YALE UNIVERSITY · PI John H. Krystal, LUCILA OHNO-MACHADO · 2016 to 2026
$102.9MYale SPORE in Lung Cancer (YSILC): The Biology and Personalized Treatment of Lung CancerP50CA196530 · NCI · YALE UNIVERSITY · PI Roy S Herbst · 2015 to 2026
$31.1MGenomics of rapid adaptation in the lab and in the wildR35GM118165 · NIGMS · STANFORD UNIVERSITY · PI Dmitri Petrov · 2016 to 2026
$8.3MMutant EGF Receptor-Dependent Lung Cancer in Human Cell Lines and Transgenic MiceR01CA120247 · NCI · YALE UNIVERSITY · PI POLITI, KATERINA ABIGAIL · 2006 to 2014
$3.8MUnraveling mechanisms of tumor suppression in lung cancerR01CA234349 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2019 to 2023
$2.4M(PQ4) Quantitative and multiplexed analysis of gene function in cancer in vivoR01CA231253 · NCI · STANFORD UNIVERSITY · PI PETROV, DMITRI, WINSLOW, MONTE MEIER · 2018 to 2022
$2.3MMechanisms of Response and Resistance to Immune Checkpoint Inhibitors in Lung AdenocarcinomaF32CA210516 · NCI · YALE UNIVERSITY · PI HASTINGS, KATHERINE RENEE AMATO · 2017 to 2018
$116kModulation of the Immune System as a Strategy to Treat EGFR Mutant Lung AdenocarcinomaF31CA203488 · NCI · YALE UNIVERSITY · PI AYENI, DEBORAH O · 2015 to 2017
$56kNCATS NIH HHS UL1 TR001863NCI NIH HHS F31 CA203488NCI NIH HHS F32 CA210516NCI NIH HHS P50 CA196530NCI NIH HHS R01 CA120247NCI NIH HHS R01 CA231253NCI NIH HHS R01 CA234349NIGMS NIH HHS R35 GM118165
Abstract
In lung adenocarcinoma, oncogenic
Indexed as
AcrylamidesAdenocarcinoma of LungAniline CompoundsAnimalsAntineoplastic AgentsDisease Models, AnimalErbB ReceptorsFemaleHumansIndolesLung NeoplasmsMaleMicePyrimidinesAcrylamidesAniline CompoundsAntineoplastic AgentsErbB ReceptorsIndolesosimertinibPyrimidines
Identifiers
What OpenQuestion holds
Textmetadata
LicenceTDM
Read underepoch 390
Registered trials
None linked
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.